Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Obesity (Silver Spring). 2011 Feb 24;19(8):1601–1608. doi: 10.1038/oby.2011.27

Table 4.

Group mean measures of binding potential (BPND) for the four testing conditions and percent changes to the neutralplacebo condition for the caudate nucleus, putamen, and ventral striatum

Caudate nucleus Putamen Ventral striatum
BPND % Change BPND % Change BPND % Change
Binge eaters
    Neutralplacebo 2.79 ± 0.49 3.38 ± 0.54 2.64 ± 0.52
    NeutralMPH 2.55 ± 0.54 +7.8 ± 16.2 3.36 ± 0.66 +0.7 ± 9.5   2.81 ± 0.54 −8.1 ± 18.6
    Foodplacebo 2.80 ± 0.55 −0.7 ± 11.9 3.46 ± 0.63 −2.3 ± 10.3 2.99 ± 0.67 −14.8 ± 21.6
    FoodMPH 2.53 ± 0.4a +8.8 ± 6.7   3.17 ± 0.5 +5.8 ± 7.8   2.54 ± 0.43 +1.4 ± 20.4
Nonbinge eaters
    Neutralplacebo 2.50 ± 0.31 3.07 ± 0.39 2.28 ± 0.47
    NeutralMPH 2.22 ± 0.4b +11.9 ± 9.8   2.75 ± 0.55 +10.6 ± 14.4 2.22 ± 0.51 +0.8 ± 24.7
    Foodplacebo 2.41 ± 0.56 +4.6 ± 15.1 2.95 ± 0.62 +4.0 ± 17.5 2.45 ± 0.54 −9.6 ± 15.2
    FoodMPH 2.47 ± 0.4a +1.1 ± 6.7   3.06 ± 0.48 +0.2 ± 10.2 2.41 ± 0.28 −8.2 ± 18.9

Percent changes are calculated with respected to neutralplacebo, which served as baseline condition.

MPH, methylphenidate.

a

Comparison of foodMPH with neutralplacebo, binge eaters had greater change than nonbinge eater (scan × diagnosis, P = 0.026).

b

Significant between neutralplacebo and neutralMPH in nonbinge eaters (P = 0.003).